银屑病网状Meta分析:概况与批判性讨论
该研究系统检索PubMed并纳入27篇银屑病网状Meta分析(NMA),评估其方法学与报告质量。仅8篇(29.6%)在PROSPERO注册,17篇(63%)报告遵循PRISMA。NMA间PASI 75疗效排名一致性高,但方法学标准化不足。
要点
- 银屑病NMA多关注诱导期疗效(第10-16周),长期结局分析少。
- 仅29.6%的NMA在PROSPERO注册,63%报告遵循PRISMA,方法学报告不足。
- 基于PASI 75的NMA疗效排名在各项研究间一致性高。
核心结论
- 银屑病NMA虽在疗效排名上高度可比,但方法学质量报告不足且PROSPERO注册率低,需加强标准化。
研究设计与样本
- 基于PRISMA标准的系统文献检索,纳入27篇银屑病NMA,平均每篇包含43项临床试验。
主要发现
- 27篇NMA中仅8篇(29.6%)在PROSPERO注册,17篇(63%)报告遵循PRISMA。
- 最常纳入的药物为乌司奴单抗(27篇)、阿达木单抗(25篇)、英夫利西单抗和依那西普(各24篇)。
- 最常用结局为PASI 75(25篇)和PASI 90(24篇),DLQI仅10篇。
- 25篇NMA评估诱导期疗效(第10-16周),仅4篇评估长期结局(第48-56周)。
临床怎么用
- 临床解读银屑病NMA时需注意其方法学报告和注册信息可能不完整。
- 基于PASI 75的疗效排名在不同NMA间一致性较高,可辅助治疗决策。
局限性
- 未报告NMA质量评价的充分信息,PROSPERO注册标准未普遍遵循。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Network meta-analyses (NMAs) increasingly assist in treatment decisions in disease areas such as psoriasis, where data from multiple clinical trials (CTs) on a growing number of different drugs become available. This study aimed to characterize NMAs published in psoriasis. A systematic literature search in PubMed was conducted using a structured search protocol based on the PRISMA criteria. Twenty-seven NMAs were identified, including an average of 43 CTs per NMA. Only eight of 27 NMAs (29.6%) were documented in the PROSPERO registry and only 17 (63%) reported following the PRISMA criteria. The mean number of patients per NMA was 19 624 (range: 6113-51 749). Across all NMAs, the drugs most frequently included were ustekinumab (n = 27 NMAs), followed by adalimumab (n = 25), infliximab and etanercept (n = 24 each). In all n = 27 NMAs, placebo comparisons and in n = 25, comparisons with active controls were used for bridging. Effect estimates were performed in all cases, SUCRA in 14. Most frequently used outcomes were Psoriasis Area and Severity Index (PASI) 75 (n = 25) and PASI 90 (n = 24), and Dermatology Life Quality Index (n = 10). NMAs mostly measured induction efficacy (weeks 10-16, n = 25) but rarely long-term outcomes (weeks 48-56, n = 4). Sensitivity analyses were performed in n = 17 (63%) of the studies. Main results varied considerably between studies and depended on the year of publication and thus the number of available drugs and studies. However, the concordance between NMA efficacy rankings based on PASI 75 was high. Although a large number of NMAs have been published on psoriasis showing highly comparable results on efficacy, no sufficient information on the quality criteria was reported, and PROSPERO registry criteria were not followed. This argues in favour of greater standardization of NMA methodology and reporting.
引用
- Augustin M, Valencia López M, Reich K, et al. Network meta-analyses in psoriasis: overview and critical discussion. J Eur Acad Dermatol Venereol. 2021. PMID: 34506643. doi:10.1111/jdv.17650
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。